Researchers from the dermatology departments at Roskilde & Gentofte Hospitals in Copenhagen have been awarded gold by the 22nd World Congress of Dermatology for their study on how optical coherence tomography (OCT) can monitor the effectiveness of photodynamic therapy (PDT) on superficial basal cell carcinomas.
The investigation was conducted using Michelson Diagnostics' VivoSight OCT scanner.
The study describes OCT morphology in nonmelanoma skin cancer (NMSC) lesions during PDT and assesses how OCT morphology before, during, and after treatment reflects the treatment outcome at three-month followup.
The benefit of photodynamic therapy of NMSCs over conventional surgical excision is its noninvasive approach to avoid surgery scars. This type of skin cancer frequently occurs on the face, where disfiguring scars are highly undesirable.
The VivoSight scanner uses OCT to provide images of subsurface tissue similar to ultrasound, but at a greater resolution, enabling the clinician to see critical details of the skin epidermis and dermis in real-time.
The VivoSight Topical OCT system is indicated for use in 2D, cross-sectional, real-time imaging of external tissues of the human body. This indicated use allows imaging of tissue microstructure, including skin, to aid trained and competent clinicians in their assessment of a patient's clinical conditions.
Michelson Diagnostics has received clearance in Europe and the U.S. to market the scanner, which is being evaluated at cancer clinics on both continents.
